Showing 2,427 news articles about HIV treatment

Filters Content type: Editors' picks Topic: HIV treatment

Treatment is recommended for all people living with HIV. It involves taking a combination of antiretroviral drugs. This stops the virus from replicating and allows the immune system to strengthen and fight infections.

HIV treatment

US FDA Approves New Biktarvy Indication For People With HIV Who Are Treatment Experienced And Restarting Antiretroviral Treatment

Editor's pick
Gilead Sciences press release
4 August 2025
Treatment simplification strategies

Switching to dual ART after durable suppression in West and Central Africa

Editor's pick
i-Base
4 August 2025
Weight gain & lipodystrophy

Weight Gain Linked to Lower Quality of Life in HIV

Editor's pick
American Journal of Managed Care
4 August 2025
New & experimental HIV treatments

Ulonivirine Shows Promise for Weekly Oral HIV Treatment

Editor's pick
POZ
4 August 2025
Weight gain & lipodystrophy

GLP-1s and HIV: What You Need to Know Before Starting

Editor's pick
TheBody
4 August 2025
Weight gain & lipodystrophy

Weight Gain and HIV: It’s Not the Antiretrovirals, 3-Year Study Finds

Editor's pick
TheBodyPro
26 July 2025
Injectable & long-acting HIV treatment

Large, Diverse Study Backs Use of Long-Acting Injectable ART for Individuals With Viremia

Editor's pick
TheBodyPro
24 July 2025
Support issues for children & young people

New WHO guidance on HIV disclosure for children and adolescents

Editor's pick
World Health Organization
21 July 2025
Injectable & long-acting HIV treatment

ViiV Healthcare and Medicines Patent Pool extend voluntary licensing agreement to enable access to long-acting injectable HIV treatment

Editor's pick
Medicines Patent Pool
15 July 2025
PEP

2025 Updates to US HIV nPEP Guidelines: Many Welcome Changes—and One Concern

Editor's pick
TheBodyPro
10 July 2025
Cardiovascular disease

Popular HIV Drug Linked to Higher Risk for MACE

Editor's pick
Medscape (requires free registration)
10 July 2025
New & experimental HIV treatments

U.S. FDA Accepts New Drug Application for Merck’s Doravirine/Islatravir, an Investigational, Once-Daily, Oral, Two-Drug Regimen for Treatment of Adults with Virologically Suppressed HIV-1 Infection

Editor's pick
Merck press release
10 July 2025
Treatment guidelines

US: Decline of Nonrecommended HIV Care in Medicare

Editor's pick
Medscape (requires free registration)
7 July 2025
Improving HIV care

ECDC releases new standards to improve HIV prevention and care

Editor's pick
European Centre for Disease Prevention and Control (ECDC)
27 June 2025
Treatment guidelines

Federal HIV Guidelines Face a Shutdown — A Critical Loss for Clinicians and Patients

Editor's pick
HIV and ID Observations
24 June 2025
The search for a cure

Could Lipid Nanoparticles and mRNA Truly Be Our Path to an HIV Cure?

Editor's pick
TheBodyPro
24 June 2025
Injectable & long-acting HIV treatment

Long-acting injectable HIV treatment highly effective in people with a detectable viral load and adherence challenges

Editor's pick
CATIE
17 June 2025
Cardiovascular disease

Abacavir-Based ART Regimens Linked to Higher MACE Risk in Patients With HIV

Editor's pick
Infectious Disease Advisor
12 June 2025
New & experimental HIV treatments

FDA Pauses Trials of Two Experimental Long-Acting HIV Drugs

Editor's pick
POZ
12 June 2025
Sexually transmitted infections prevention

BASHH publishes UK-first guidelines on doxyPEP for the prevention of syphilis

Editor's pick
British Association for Sexual Health and HIV (BASHH)
9 June 2025
HIV treatment

Generic Version of HIV Drug Recommended for EU

Editor's pick
Medscape (requires free registration)
26 May 2025
Access to healthcare

Reducing dosing: a possible crisis response to ART stock-outs and closed clinics

Editor's pick
i-Base
5 May 2025
People with limited treatment options

Lenacapavir EAP in the UK closed to new referrals: NHS England and Gilead fail to agree a price after more than two years

Editor's pick
i-Base
22 April 2025
Injectable & long-acting HIV treatment

Potential for bictegravir and dolutegravir to overcome resistance to CAB/RPV-LA

Editor's pick
i-Base
14 April 2025